Down 12%, Should You Buy the Dip on Eli Lilly?
Eli Lilly (NYSE: LLY) has been a great growth pick for investors over the past few years. The pharma company, thanks to its weight loss drug portfolio, has seen revenue climb in the double digits -- and as a result, the stock has taken off, climbing more than 170% in three years.You may recognize the names of these blockbusters driving Lilly's growth, as they've been widely talked about across the media. Lilly sells tirzepatide, commercialized as Zepbound for weight loss and Mounjaro for type 2 diabetes. Doctors have prescribed either for the weight loss indication, and together, the two drugs generated more than $16 billion in revenue for Lilly last year.On top of this, Lilly has a broad portfolio of drugs targeting a wide range of indications, so this company doesn't rely uniquely on one treatment area -- though the weight loss portfolio has been the focus in recent times due to its performance so far and future prospects.Continue reading
Eli Lilly (NYSE: LLY) has been a great growth pick for investors over the past few years. The pharma company, thanks to its weight loss drug portfolio, has seen revenue climb in the double digits -- and as a result, the stock has taken off, climbing more than 170% in three years.
You may recognize the names of these blockbusters driving Lilly's growth, as they've been widely talked about across the media. Lilly sells tirzepatide, commercialized as Zepbound for weight loss and Mounjaro for type 2 diabetes. Doctors have prescribed either for the weight loss indication, and together, the two drugs generated more than $16 billion in revenue for Lilly last year.
On top of this, Lilly has a broad portfolio of drugs targeting a wide range of indications, so this company doesn't rely uniquely on one treatment area -- though the weight loss portfolio has been the focus in recent times due to its performance so far and future prospects.
